http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021207606-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_751562df05f1831baef905641425c407
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
filingDate 2021-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7de576d9daee89011ae12c9ec6308e9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f602e3cef4acc3dd5eb290e597b1e12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d921523cdbc4edfead1374f86fd40eef
publicationDate 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021207606-A1
titleOfInvention Methods for treatment of coronavirus infections
abstract Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can be therapeutic and/or prophylactic. The amount of probenecid, metabolite or analog thereof, or pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such asSARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021245107-A3
priorityDate 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020247665-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013280806-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005112554-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013136770-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395793
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4911

Total number of triples: 22.